Received: 1 March 2021
Accepted: 28 July 2021
First Online: 23 August 2021
: This was a <i>post-hoc</i> analysis of a 2-year, prospective, international, observational study, and all data collected were anonymised to preserve participant anonymity and confidentiality. Approval from ethics committee was obtained (CT 1, Azienda Ospedaliero Universitaria Policlinico Vittori Emanuele Catania Comitato Etica, Via Santa), and sites were requested to obtain written informed consent from each patient prior to inclusion into the study.
: Not applicable
: FP has received personal compensation for speaking activities and serving on an advisory board by Almirall, Bayer, Biogen, Celgene, Merck, Novartis, Roche, Sanofi Genzyme, and TEVA. He also received research grants by Biogen, Merck, FISM (Fondazione Italiana Sclerosi Multipla), RELOAD Onlus Association, and University of Catania.JP is an employee at Bayer AG.LZ was an employee of Parexel at the time of this analysis.EW is an employee at Bayer AG.